ImageneBio, Inc.
$6
▼
-1.58%
2026-04-21 07:29:00
www.inmagenebio.com
NCM: IMA
Explore ImageneBio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$65.99 M
Current Price
$6
52W High / Low
$18 / $3.94
Stock P/E
—
Book Value
$11.91
Dividend Yield
—
ROCE
-34.18%
ROE
-68.91%
Face Value
—
EPS
$-9.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
—
Debt / Equity
2.23
Current Ratio
12.49
Quick Ratio
12.49
Forward P/E
-1.46
Price / Sales
68.53
Enterprise Value
$-77.55 M
EV / EBITDA
1.61
EV / Revenue
-96.93
Rating
None
Target Price
$16
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 2. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 3. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 4. | ORIC Pharmaceuticals, Inc. | $10.89 | — | $1.09 B | — | -36.81% | -41.27% | $14.93 / $4.52 | $3.9 |
| 5. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 6. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 7. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 3.5 M |
| Operating Profit | -8.5 M | -26.59 M | -6.14 M | -2.04 M |
| Net Profit | -6.91 M | -24.78 M | -4.81 M | -3.18 M |
| EPS in Rs | -0.62 | -2.22 | -0.43 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0.8 M | 3.5 M | 7.96 M |
| Operating Profit | -48.45 M | -37 M | -21.93 M |
| Net Profit | -45.35 M | -36.57 M | -21.15 M |
| EPS in Rs | -4.05 | -3.27 | -1.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 152.98 M | 15.92 M | 31.25 M |
| Total Liabilities | 19.84 M | 176.49 M | 157.35 M |
| Equity | 133.14 M | -160.56 M | -126.11 M |
| Current Assets | 140.29 M | 12.47 M | 25.9 M |
| Current Liabilities | 11.23 M | 17.21 M | 9.49 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -47.84 M | -21.32 M | -18.23 M |
| Investing CF | -5.81 M | 11.12 M | -10.45 M |
| Financing CF | 135.47 M | 6.91 M | 0.15 M |
| Free CF | -47.84 M | -21.32 M | -18.54 M |
| Capex | — | — | -0.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | -77.14% | -56.04% | — |
| Earnings Growth % | -24.01% | -72.91% | — |
| Profit Margin % | -5668.62% | -1044.8% | -265.61% |
| Operating Margin % | -6056.38% | -1057.14% | -275.37% |
| Gross Margin % | — | — | — |
| EBITDA Margin % | -5927.25% | -1013.54% | -236.5% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-28 | 1:0.0833333 |